LLY — Eli Lilly and Company
Is LLY overbought or oversold? Here is the current MarketMoodz read.
Eli Lilly and Company (LLY) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Pharmaceuticals) last closed at $1431.67. The rating moved from Neutral to Overbought on November 12, 2026.
- Public ratingOverbought (as of November 17, 2026)
- Last close$1431.67
- Last changeMoved from Neutral to Overbought on November 12, 2026
- SectorHealthcare
- IndustryPharmaceuticals
See all overbought Healthcare stocks →
AI analysis
Eli Lilly and Company (LLY) displays strong commercial momentum driven by its obesity/GLP-1 franchise, diversified large-cap pharma characteristics and healthy cash generation to fund R&D and selective M&A. Recent positive sector readthroughs reduce near-term binary risks around obesity labeling and support continued defensive flows into major pharma names. Key catalysts include sustained prescription uptake, international expansion and pipeline readouts, while principal concerns are competitive share shifts, payer resistance and potential safety or policy developments that could pressure pricing and growth.
Key factors
- Eli Lilly and Company (LLY) benefits from a market-leading position in obesity/GLP-1/tirzepatide class drugs with strong revenue visibility and high margins
- Large-cap pharma defensiveness: investors are rotating into big, diversified pharmaceutical names amid policy uncertainty, supporting relative demand for LLY shares
- Positive readthrough from Novo Nordisk obesity data reduces tail risk around labeling/payer pushback for obesity therapies, improving sector sentiment and uptake assumptions
- Robust free cash flow and balance-sheet flexibility that support ongoing R&D investment, targeted business development, and potential share-repurchase programs
- Broad pipeline across multiple therapeutic areas and established commercial infrastructure that accelerate launch execution and international expansion
- Recent corporate actions (dealmaking outside obesity) indicate strategic diversification of revenue streams beyond a single franchise
Risks
- Intensifying competition from Novo Nordisk and other GLP-1/amylin entrants that could pressure pricing and market share in obesity and diabetes
- Payer resistance, pricing pressure, or accelerated regulatory scrutiny on obesity/weight-loss therapies leading to formulary restrictions or margin erosion
- Product-safety or adverse-event developments that could slow uptake, trigger label changes, or prompt litigation
- Policy and macro risks (drug-pricing reforms, Medicare leverage) that could materially affect revenue or margin assumptions
- Manufacturing or supply-chain disruptions that constrain availability during peak launch periods
- Valuation sensitivity — high expectations are priced into shares and disappointments could produce significant multiple contraction
Latest MarketMoodz coverage
- From mouthwash to hair dye: Weight‑loss jabs reshape UK shopping2026-07-07
- Innovent, Lilly Expand Verzenios Commercialization in China2026-07-01
- Medicare to Temporarily Cover GLP‑1 Obesity Drugs Starting July 1, 20262026-06-30
- FDA Selects Firms for PreCheck to Speed New Drug Plants2026-06-29
- Chip Stocks Rally as Goldman’s M&A Streak Spurs Rotation2026-06-29
See today's live rating, score and targets
Members see the live hourly rating for LLY — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.